Drug Trial Radar · NCT07679828
Polypills Approach for Multiple Cardiovascular Risk Factors
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8,252
Planned (sponsor's estimate)
Start
Jul 11, 2026
Primary completion
Dec 31, 2029
Study completion Mar 1, 2030
Sponsor
- Lead sponsor
- China Medical University, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 1, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for the integrated management of hypertension, dyslipidemia, and type 2 diabetes among adults aged 50 to 75 years without prior cardiovascular disease in China. The trial will evaluate whether a fixed-dose combination strategy improves the 10-year cardiovascular disease risk estimated using the PREVENT equations at Phase 1. Participants will be further followed to determine whether the fixed-dose combination strategy reduces major cardiovascular events and improves cognitive outcomes compared with usual care at Phase 2.
Conditions
- Hypertension
- Dyslipidemia
- Diabetes
Interventions
Fixed-Dose Combination StrategyDrug
Participants assigned to the intervention group will receive a fixed-dose combination strategy for the integrated control of blood pressure, lipid, and glucose. Eight prespecified fixed-dose formulations will be used, differing in antihypertensive intensity and rosuvastatin dose. All formulations will include olmesartan medoxomil/amlodipine, rosuvastatin, ezetimibe 10 mg, and dapagliflozin 10 mg, with indapamide 2.5 mg included in selected formulations. The olmesartan medoxomil/amlodipine dose will range from 5/1.25 mg to 20/5 mg, and the rosuvastatin dose will be either 5 mg or 10 mg. Treatment will be selected and adjusted among the prespecified fixed-dose formulations according to participants' blood pressure levels, treatment targets, tolerability, and safety. If the prespecified blood pressure, lipid, or glycemic targets are not achieved despite the highest fixed-dose regimen, additional open-label medications may be prescribed according to guideline recommendations.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 10-year CVD riskTime frame: 12 months
- Composite cardiovascular disease outcomeTime frame: 36 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Henan University of Chinese Medicine
Zhengzhou, Henan, China · Not yet recruiting
Affiliated Hospital of Chifeng University
Chifeng, Inner Mongolia, China · Recruiting
Tongliao People's Hospital
Tongliao, Inner Mongolia, China · Not yet recruiting
Kunshan Hospital of Chinese Medicine
Kunshan, Jiangsu, China · Not yet recruiting
Suzhou Wujiang District Hospital of Traditional Chinese Medicine
Suzhou, Jiangsu, China · Not yet recruiting
The Fifth People's Hospital of Wujiang District
Suzhou, Jiangsu, China · Not yet recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
Taixing Second People's Hospital
Taizhou, Jiangsu, China · Not yet recruiting
Central Hospital of Jinzhou
Jinzhou, Liaoning, China · Recruiting
Panjin Central Hospital
Panjin, Liaoning, China · Not yet recruiting
First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
Tieling Central Hospital
Tieling, Liaoning, China · Recruiting
Tiemei General Hospital of Liaoning Health Industry Group
Tieling, Liaoning, China · Recruiting
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.